Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPL344 in ALS
NCT03652805Phase 2Suspended
- Sponsor
- Immunity Pharma
- Start
- Aug 2018
- Primary completion
- Jan 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IPL344 in amyotrophic lateral sclerosis (ALS), sponsored by Immunity Pharma. Primary endpoints: Adverse Events (AEs) and Serious Adverse Events (SAEs) and Maximum Tolerated Dose. Started Aug 2018; status: suspended.
02
Drugs
IPL344
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03652805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03652805.